VRX - Valeant Pharmaceuticals International, Inc.

NYSE - NYSE Delayed Price. Currency in USD
24.27
-0.45 (-1.82%)
At close: 4:03PM EDT
Stock chart is not supported by your current browser
Previous Close24.72
Open24.29
Bid0.00 x 1000
Ask0.00 x 2900
Day's Range23.82 - 24.47
52 Week Range10.94 - 27.79
Volume6,174,842
Avg. Volume8,315,043
Market Cap8.477B
Beta-0.94
PE Ratio (TTM)3.55
EPS (TTM)6.83
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-11-10
1y Target Est21.93
Trade prices are not sourced from all markets
  • MARKETS: Here's why stocks are dropping right now
    Yahoo Finance Video8 days ago

    MARKETS: Here's why stocks are dropping right now

    Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after the Trump administration released details on the latest round of China tariffs, to which China has responded in kind. In other news, the June Empire State Manufacturing Survey beat Wall Street expectations on nearly every front.

  • CNBC11 hours ago

    Cramer's lightning round: I don't like Snap's ownership structure

    Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a much debated social media play.

  • The woman behind 'female Viagra' sold her company for $1 billion — then got it back for free
    CNBC2 days ago

    The woman behind 'female Viagra' sold her company for $1 billion — then got it back for free

    Cindy Eckert is the anti-Martin Shkreli — after the billion-dollar Valeant debacle, the founder of Sprout Pharmaceuticals is back as CEO and she's slashed the price of the little pink libido pill for women. Here's what she learned from the experience and where she goes from here.

  • Forbes3 days ago

    There Go Those Drug Companies Inventing New Diseases Again

    Another quote used by Walsh, this one from Cindy Pearson of the National Women’s Health Network, claims that “Osteopenia is disease-mongering plain and simple.” Osteopenia is a term used to describe bone-thinning and is considered to be the mid-point between healthy bone and osteoporosis. Is osteopenia (bone-thinning) a disease?

  • PR Newswire4 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valeant Pharmaceuticals International, Inc. - VRX

    NEW YORK , June 19, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (NYSE: VRX).   ...

  • PR Newswire4 days ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Valeant Pharmaceuticals International, Inc. (VRX)

    NEW YORK , June 19, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Valeant Pharmaceuticals International, Inc. ...

  • Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis
    Zacks4 days ago

    Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis

    Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.

  • Barrons.com4 days ago

    Valeant's FDA Letter: Don't Write Off the Stock Yet

    Shares of Valeant Pharmaceuticals International (VRX) started the week off on a down note, on news that the company received a Complete Response Letter from the Food and Drug Administration concerning its plaque psoriasis treatment Monday, and the shares are falling again today. Cantor Fitzgerald argued that the letter wasn't anything for investors to worry about, and today H.C. Wainwright analyst Raghuram Selvaraju argues much the same thing, even if he has a Neutral rating on the stock. Selvaraju writes that although the psoriasis drug, Duobrii, was one of the "Significant Seven" products around which he saw the "new" Valeant would be built, he--much like Cantor--hasn't included sales from the treatment in his model for 2018.

  • Company News For Jun 19, 2018
    Zacks4 days ago

    Company News For Jun 19, 2018

    Companies in the news are: JD,GOOGL,VRX,SLDB,TSLA

  • Why Valeant Pharmaceuticals' Stock Tumbled 12.3% Today
    Motley Fool5 days ago

    Why Valeant Pharmaceuticals' Stock Tumbled 12.3% Today

    The FDA has dealt the company some disappointing news on one of its late-stage drugs.

  • What Happened in the Stock Market Today
    Motley Fool5 days ago

    What Happened in the Stock Market Today

    On a day stocks fell on trade worries, Google announced a big investment, and Valeant Pharmaceuticals got a rejection from the FDA.

  • Valeant’s Rebound Falters After Key Drug Is Rejected
    Bloomberg5 days ago

    Valeant’s Rebound Falters After Key Drug Is Rejected

    Valeant Pharmaceuticals International Inc.’s rebound from this year’s low in March was stopped in its tracks after U.S. regulators rejected its application for a plaque psoriasis lotion, Duobrii, that management saw as the first of many new drugs to hit the market in the next few years. Trading volume was more than 1.5 times the full-day average of the past three months as investors retreated even after the company pointed out that the Food and Drug Administration’s ruling was related to its pharmacokinetic data and said management is working to “resolve this matter expeditiously” and has already requested a meeting with regulators. Wells Fargo analyst David Maris warned that an approval may be delayed by six to nine months depending on Valeant’s need to generate additional data.

  • Valeant Stock Was Having a Pretty Good 2018—Until Today
    Fortune5 days ago

    Valeant Stock Was Having a Pretty Good 2018—Until Today

    Valeant shed 8% of its market value on Monday. Here's why.

  • Valeant Pharmaceuticals Intl Inc Shares Sink on Psoriasis Treatment Rejection by FDA
    InvestorPlace5 days ago

    Valeant Pharmaceuticals Intl Inc Shares Sink on Psoriasis Treatment Rejection by FDA

    Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock took a hit on Monday after the U.S. Food and Drug Administration (FDA) rejected its psoriasis treatment. The Valeant Pharmaceuticals Intl Inc treatment that was rejected by the FDA is DUOBRII. This is a lotion made by the company’s Ortho Dermatologics division to treat plaque psoriasis.

  • Reuters5 days ago

    FDA declines to approve Valeant's plaque psoriasis lotion

    Valeant Pharmaceuticals International Inc's plaque psoriasis treatment did not get approval from U.S. health regulators, a setback for the company which had high hopes for the lotion. A possible delay in approval of the treatment could be a blow to the company, as the treatment is one of the seven products, dubbed as the "Significant Seven", highlighted in Valeant's pipeline projected to raise over $1 billion over the next five years. "We wonder if Valeant will need to update this expectation for the 'Significant Seven' peak sales following the setback to Duobrii," Wells Fargo analyst David Maris said in a note.

  • Barrons.com5 days ago

    FDA Letter May Not Hamper Valeant for Long

    Shares of Valeant Pharmaceuticals International (VRX) are lower on Monday, following news that the company received a Complete Response Letter from the Food and Drug Administration concerning its plaque psoriasis treatment. Chen writes that there are three reasons why she still has confidence in Valeant: The fact that the pharmacokinetic (PK) data has been available for "years," that in April, the Journal of American Academy of Dermatology published positive results from two Phase 3 randomized double-blind clinical trials for the first time, and sales of Duobrii wouldn't have been critical to Valeant's 2018 sales, given that it would have launched late in the year.  Chen notes that the FDA's letter related to Duobrii's PK data, and Valeant is working with the agency.

  • The Wall Street Journal5 days ago

    Stocks to Watch: Apple, Facebook, Alphabet, Comcast, GE, GM, Wynn, Valeant, Chevron, Perry Ellis

    Among the companies with shares expected to trade actively in Monday's session are Apple, Facebook, Alphabet, Comcast, General Electric and General Motors.

  • MarketWatch5 days ago

    Valeant shares drop 5% after FDA fails to approve plaque psoriasis lotion

    Valeant Pharmaceuticals International Inc. shares dropped 5.4% in premarket trade on Monday on news that the Food and Drug Administration failed to approve the company's lotion intended to treat plaque psoriasis. In a "complete response letter" notifying the company of the decision, the regulator noted questions about pharmacokinetic data, but did not specify problems with how well the product, Duobrii, works, nor with chemistry, manufacturing and controls processes, the company said. Valeant says it plans to work with the FDA to resolve the matter.

  • PR Newswire5 days ago

    FDA Issues Complete Response Letter For DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion

    LAVAL, Quebec, June 18, 2018 /PRNewswire/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company's New Drug Application (NDA) for DUOBRII™1 (halobetasol propionate and tazarotene) (IDP-118) lotion in the treatment of plaque psoriasis. The CRL only noted questions regarding pharmacokinetic data," said Joseph C. Papa, chairman and CEO, Valeant. "We are working to resolve this matter expeditiously and have already requested a meeting with the FDA.

  • InvestorPlace8 days ago

    Can Sprout Pharma’s Latest Revival Really Boost VRX Stock?

    Now, Sprout Pharmaceuticals will make a second attempt to sell the drug but using a different method. Most importantly, Sprout will sell the drug for just $400, a 50% markdown from Valeant’s selling price. Both companies have an interest in getting patients prescribed on Addyi.

  • Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play
    InvestorPlace8 days ago

    Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play

    The U.S. government is shifting its focus from accusing drug companies of overcharging to encouraging the marketplace to operate more competitively. On May 31, FDA Commissioner Scott Gottlieb, announced a draft guidance that will limit drug companies in delaying generics to market. Previously, generics needed to negotiate with branded firms.

  • Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
    Zacks8 days ago

    Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

    Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

  • PR Newswire9 days ago

    Bausch + Lomb Launches Soothe® Xtra Protection Preservative Free Lubricant Eye Drops

    Now Available at Major U.S. Retailers LAVAL, Quebec , June 14, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International ...

  • Drug Stocks: The Next Hot Industry or Value Traps?
    Zacks9 days ago

    Drug Stocks: The Next Hot Industry or Value Traps?

    These 5 stocks look dirt cheap but is it too good to be true?

  • What Cindy Eckert has planned with Sprout, Addyi back in hands
    American City Business Journals10 days ago

    What Cindy Eckert has planned with Sprout, Addyi back in hands

    It’s take two for Sprout Pharmaceuticals and Addyi, the only drug approved by the U.S. Food and Drug Administration to treat low sexual desire disorder (HSDD) in women.